Cell-Penetrating Peptide cLK Delivers Bone-Forming Transcription Factor into Stem Cells
A cyclic alpha-helical cell-penetrating peptide (cLK) delivered the bone-forming factor Runx2 into mesenchymal stem cells more effectively than Tat, enhancing osteogenic differentiation by 1.2-fold.
Quick Facts
What This Study Found
The cyclic cLK peptide delivered fragmented Runx2 into stem cells more efficiently than Tat-CPP, producing 1.2-fold greater mineralization and higher osteogenic gene expression.
Key Numbers
cLK enhanced fRunx2 penetration; 1.2x more alizarin red vs Tat; higher ALP and osteocalcin gene expression
How They Did This
In-vitro study comparing cLK and Tat peptide delivery of fluorescently labeled fragmented Runx2 into MC3T3 cells and rat mesenchymal stem cells, measuring uptake, mineralization, and gene expression.
Why This Research Matters
Bone regeneration therapies need efficient ways to program stem cells. Delivering transcription factors via CPPs could guide bone formation without genetic manipulation, advancing regenerative medicine.
The Bigger Picture
This demonstrates that CPP-delivered transcription factors can direct stem cell fate, offering a non-viral, non-genetic approach to tissue engineering and bone regeneration.
What This Study Doesn't Tell Us
In-vitro study only; 1.2-fold improvement is modest; no in-vivo bone formation testing; long-term effects and optimal dosing not established.
Questions This Raises
- ?Can cLK-Runx2 delivery promote bone formation in vivo in animal fracture models?
- ?Would repeated dosing improve the modest 1.2-fold enhancement?
- ?Could this CPP-transcription factor approach work for other tissue types beyond bone?
Trust & Context
- Key Stat:
- 1.2-fold more mineralization cLK-delivered Runx2 produced more calcium deposition than Tat-delivered Runx2 in mesenchymal stem cells
- Evidence Grade:
- Proof-of-concept in-vitro study with appropriate controls and multiple outcome measures, but modest effect size and no in-vivo validation.
- Study Age:
- Published in 2020; CPP-mediated transcription factor delivery for bone regeneration remains an emerging research area.
- Original Title:
- Augmented osteogenesis of mesenchymal stem cells using a fragmented Runx2 mixed with cell-penetrating, dimeric a-helical peptide.
- Published In:
- European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 144, 105210 (2020)
- Authors:
- Nam, So Hee(2), Lee, Yan(2), Ahn, Joon Hyung, Chung, Chun Kee, Yang, Hee-Jin, Park, Sung Bae, Jang, Sangmok
- Database ID:
- RPEP-05024
Evidence Hierarchy
Frequently Asked Questions
Can peptides help grow bone?
Cell-penetrating peptides can deliver bone-forming transcription factors like Runx2 into stem cells, directing them to become bone cells without genetic modification.
What is cLK peptide?
A cyclic alpha-helical cell-penetrating peptide made of leucine and lysine residues that enters cells more effectively than the standard Tat CPP for delivering molecular cargo.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05024APA
Nam, So Hee; Lee, Yan; Ahn, Joon Hyung; Chung, Chun Kee; Yang, Hee-Jin; Park, Sung Bae; Jang, Sangmok. (2020). Augmented osteogenesis of mesenchymal stem cells using a fragmented Runx2 mixed with cell-penetrating, dimeric a-helical peptide.. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 144, 105210. https://doi.org/10.1016/j.ejps.2019.105210
MLA
Nam, So Hee, et al. "Augmented osteogenesis of mesenchymal stem cells using a fragmented Runx2 mixed with cell-penetrating, dimeric a-helical peptide.." European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2020. https://doi.org/10.1016/j.ejps.2019.105210
RethinkPeptides
RethinkPeptides Research Database. "Augmented osteogenesis of mesenchymal stem cells using a fra..." RPEP-05024. Retrieved from https://rethinkpeptides.com/research/nam-2020-augmented-osteogenesis-of-mesenchymal
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.